NCT05047146
Completed
Not Applicable
The Clinicopathological and Prognostic Factors of Hepatocellular Carcinoma; 10 Years' Tertiary Center Experience in Egypt
Sadat City University1 site in 1 country530 target enrollmentJanuary 1, 2021
ConditionsHepatocellular Carcinoma
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hepatocellular Carcinoma
- Sponsor
- Sadat City University
- Enrollment
- 530
- Locations
- 1
- Primary Endpoint
- Clinicopathological factors of Hepatocellular Carcinoma
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This study aimed at study the clinical and pathological criteria of Hepatocellular carcinoma to keep with new challenging in diagnosis and morpho-molecular classifications
Investigators
Mahmoud Samy Abdallah
Lecturer of Clinical Pharmacy
Sadat City University
Eligibility Criteria
Inclusion Criteria
- •All pathologically proven Hepatocellular Carcinoma
Exclusion Criteria
- •Other malignant tumors than Hepatocellular Carcinoma
- •Benign tumor
Outcomes
Primary Outcomes
Clinicopathological factors of Hepatocellular Carcinoma
Time Frame: 10 years
The reserve of background liver
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Clinicopathological factors in hepatocellular carcinoma with microscopic portal vein invasion.Hepatocellular carcinomaJPRN-UMIN000017852Department of Gastroenterological surgery I, Hokkaido University
Not yet recruiting
Not Applicable
Clinical study of liver cancerHealth Condition 1: C220- Liver cell carcinomaCTRI/2023/02/049609Kasturba Medical College, Manipal
Completed
Not Applicable
Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic ModellingHepatocellular CarcinomaAdjuvant ImmunotherapyCheckpoint InhibitorNCT06298123Chen Xiaoping304
Unknown
Not Applicable
Risk of Hepatocellular Carcinoma in Patient With Liver CirrhosisCarcinoma, HepatocellularNCT03083002University of Modena and Reggio Emilia250
Recruiting
Not Applicable
Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular CarcinomaCarcinoma, HepatocellularImmunotherapyNCT06571396Qilu Hospital of Shandong University200